Therapy News and Research

RSS

CMS assigns J-code for Eisai's Halaven Injection to treat breast cancer

Eisai Inc. announced today that the Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for Halaven (eribulin mesylate) Injection.

4 Jan 2012

iCAD enters $15M debt facility agreement with Deerfield Management

iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that it has entered into a five year, $15 million debt facility agreement with Deerfield Management Company LP, a leading healthcare investment fund.

3 Jan 2012

Astellas, AVEO announce results of tivozanib and sorafenib comparison trial on RCC

AVEO Pharmaceuticals, Inc. and Astellas Pharma Inc. today announced that tivozanib demonstrated superiority over sorafenib in the primary endpoint of progression-free survival (PFS) in TIVO-1, a global, randomized Phase 3 clinical trial evaluating the efficacy and safety of investigational drug tivozanib compared to sorafenib in 517 patients with advanced renal cell carcinoma.

3 Jan 2012

InSightec completes enrollment in ExAblate Neuro clinical study for Essential Tremor

InSightec Ltd, the global leader in MR guided Focused Ultrasound therapy, announced today that it has completed enrollment in the world's first feasibility study evaluating the use of MRgFUS for treatment of Essential Tremor, using ExAblate Neuro at University of Virginia, Charlottesville, Virginia.

3 Jan 2012

FDA sets Feb. 9 for ODAC meeting to review CTI's resubmitted pixantrone NDA

Cell Therapeutics, Inc. (CTI) announced today that on February 9, 2012 the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will review CTI's resubmitted New Drug Application (NDA) for pixantrone for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) in patients who failed two or more lines of prior therapy.

3 Jan 2012

ProStrakan announces FDA approval for Transmucosal Immediate Release Fentanyl REMS Access program

ProStrakan, Inc., a subsidiary of Kyowa Hakko Kirin Co. Ltd., and an international specialty pharmaceutical company, today announces that the U.S. Food and Drug Administration has approved the TIRF (Transmucosal Immediate Release Fentanyl) REMS Access program.

31 Dec 2011

AMT raises € 2.5 million through private placement

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the Company has raised € 2.5 million in new equity by means of a private placement to three of its existing shareholders: Forbion Capital Partners, Gilde Healthcare Partners and Advent Venture Partners.

30 Dec 2011

GOG targeted therapy phase 3 clinical trial delays progression of advanced ovarian cancer

Targeted drugs, which block or disrupt particular molecules involved in the growth of tumors, have been shown to be effective treatments against many types of cancer.

29 Dec 2011

Alexion to acquire 100% of capital stock of Enobia

Alexion Pharmaceuticals, Inc. and Enobia Pharma Corp. today announced that the companies have signed a definitive agreement under which Alexion will acquire 100% of the capital stock of Enobia.

29 Dec 2011

Speedy drug metabolism more likely to cause multidrug-resistant TB

A UT Southwestern Medical Center study using a sophisticated "glass mouse" research model has found that multidrug-resistant tuberculosis (TB) is more likely caused in patients by speedy drug metabolism rather than inconsistent doses, as is widely believed.

29 Dec 2011

New initiative to detect cancers in earliest stages inside cells

A team of cancer imaging experts at Johns Hopkins has embarked on a five-year research initiative to speed development of early diagnostic tests and new treatments for breast, prostate and other common cancers.

29 Dec 2011

FitnessBuilder now available on the Web

Working out just became a whole lot easier with PumpOne's 2012 personal training experience. Launching across all major platforms for both consumers and professionals, the state-of-the-art FitnessBuilder is now available on the Web at www.fitnessbuilder.com and the Android Market in addition to its already massively successful iOS app for iPhone, iPad, and iPod touch.

28 Dec 2011

Researchers decode and characterize DNA repair mechanism

Oxidative stress is the cause of many serious diseases such as cancer, Alzheimer's, arteriosclerosis and diabetes. It occurs when the body is exposed to excessive amounts of electrically charged, aggressive oxygen compounds. These are normally produced during breathing and other metabolic processes, but also in the case of ongoing stress, exposure to UV light or X-rays. If the oxidative stress is too high, it overwhelms the body's natural defences. The aggressive oxygen compounds destroy genetic material, resulting in what are referred to as harmful 8-oxo-guanine base mutations in the DNA.

28 Dec 2011

New approach may prevent septic shock

Researchers of VIB and UGent have discovered a new approach to preventing septic shock, an often fatal extreme inflammatory reaction of the body. It is the most frequent cause of death at intensive care departments in hospitals.

28 Dec 2011

Oral and tactile sensitivities in childhood can lead to OCD

In childhood, rituals like regular schedules for meal, bath, and bed times are a healthy part of behavioral development. But combined with oral and tactile sensitivities, such as discomfort at the dentist or irritation caused by specific fabrics, these rituals could be an early warning sign of adult Obsessive Compulsive Disorder.

27 Dec 2011

CEL-SCI to expand Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation is in the process of expanding its Phase III clinical trial of the investigational therapy Multikine (Leukocyte Interleukin, Injection) to 4 additional European countries - Spain, Czech Republic, Slovakia and Croatia.

27 Dec 2011

Initial results from 22nd Century's X-22 Phase II-B smoking cessation trial

22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, today announced X-22, a prescription smoking cessation aid in development consisting of very low nicotine (VLN) cigarettes, showed a reduction of smoking from baseline over the 6-week treatment period in the company's Phase II-B clinical trial.

26 Dec 2011